ACTUATE THERAPEUTICS, INC. ACTU
company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen
synthase kinase-3 ("GSK-3"). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer
cells and block the function of the enzyme glycogen synthase kinase-3 beta ("GSK-3β"), a master regulator of complex
biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $10.3M | $18.7M | $21.7M | — |
| SG&A | $12.2M | $6.5M | $3.3M | — |
| Total operating expenses | $22.5M | $25.2M | $25.0M | — |
| Operating income | -$22.5M | -$25.2M | -$25.0M | — |
| Interest expense | $20.2K | $18.7K | $43.6K | — |
| Pre-tax income | -$22.2M | -$27.3M | -$24.7M | — |
| Income tax | $800 | $800 | $0 | — |
| Net income | -$22.2M | -$27.3M | -$24.7M | — |
| EPS, basic | -1.06 | -3.26 | -17.24 | — |
| EPS, diluted | -1.06 | -3.26 | -17.24 | — |
| Shares, diluted (wtd. avg.) | $21.0M | $8.4M | $1.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $13.2M | $8.6M | $3.0M | $20.4M |
| Total current assets | $13.6M | $9.2M | $3.0M | — |
| Total assets | $14.0M | $9.3M | $3.0M | — |
| Accounts payable | $1.5M | $1.9M | $3.4M | — |
| Total current liabilities | $5.7M | $8.8M | $6.9M | — |
| Total liabilities | $6.1M | $9.2M | $8.4M | — |
| Retained earnings | -$154.6M | -$132.4M | -$105.1M | — |
| Total equity | $7.9M | $104.2K | -$99.6M | -$75.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$19.2M | -$21.8M | -$21.6M | — |
| Stock-based compensation | $6.0M | $2.0M | $423.5K | — |
| Financing cash flow | $23.7M | $27.5M | $4.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-002257.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |